AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Phirbo (PAHC) Faces Rising Costs and Inflationary Pressure
by Zacks Equity Research
Price competition coming from cheap generic alternatives of a few Phirbo (PAHC) products is a deterrent.
QIAGEN (QGEN) to Develop Companion Diagnostic for Neuron23
by Zacks Equity Research
QIAGEN's (QGEN) novel companion diagnostic assay will help identify individuals who might benefit from Neuron23's drug candidate for Parkinson's disease.
Zacks Industry Outlook Highlights HealthEquity, AMN Healthcare and ModivCare
by Zacks Equity Research
HealthEquity, AMN Healthcare and ModivCare have been highlighted in this Industry Outlook article.
AMN Healthcare and Hudson Technologies have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
AMN Healthcare and Hudson Technologies have been highlighted as Zacks Bull and Bear of the Day.
BD's (BDX) Latest PFS Launch to Boost Production Efficiencies
by Zacks Equity Research
BD's (BDX) newest product offering is expected to set a new standard in performance for vaccine PFS with new and strict specifications for improved production efficiencies.
Haemonetics (HAE) to Offer Two VASCADE Devices in the EU
by Zacks Equity Research
Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.
Cardinal Health (CAH) Lowers Medical Segment Income Guidance
by Zacks Equity Research
Cardinal Health (CAH) projects Medical segment loss to be in the range of $25 million to $55 million for the first quarter of fiscal 2023, owing to inventory charges related to the company's gloves portfolio.
Looking for a Growth Stock? 3 Reasons Why AMN Healthcare (AMN) is a Solid Choice
by Zacks Equity Research
AMN Healthcare (AMN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Medical Services Stocks Braving Near-Term Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, AMN and MODV are set to gain the most. However, staffing shortages may disrupt the trend.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Merit Medical's (MMSI) Latest Launch to Boost Patient Care
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to ease access to difficult anatomy in the peripheral vasculature, thereby serving a wider patient pool.
AmerisourceBergen (ABC) to Buy Germany's PharmaLex for $1.3B
by Zacks Equity Research
AmerisourceBergen (ABC) inks a deal to acquire PharmaLex to support its goal to become a strategic partner of choice for pharma customers for clinical and commercial enablement solutions.
Alcon (ALC) Faces Cost Pressure, Supply Chain Disruption
by Zacks Equity Research
Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
by Zacks Equity Research
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental results.
Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.
Why Should You Add Ensign Group (ENSG) to Portfolio Now?
by Zacks Equity Research
Ensign Group (ENSG) benefits from a growing healthcare portfolio as a result of multiple facility buyouts. Solid cash-generating abilities empower ENSG to invest in growth-related initiatives.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
Globus Medical (GMED) Gains Market Share, Cost Woes Stay
by Zacks Equity Research
Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
AMN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
Charles River (CRL) to Support Cure AP-4's Clinical Trials
by Zacks Equity Research
Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $106.10, moving +0.31% from the previous trading session.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
Zimmer Biomet (ZBH) Procedure Recovery Strong, Margin Woe Stays
by Zacks Equity Research
Zimmer Biomet's (ZBH) recently completed spin-off of the non-core dental and spine business is expected to prove strategic.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Strong results across the EPD, diagnostics and medical devices businesses are driving Abbott's (ABT) top line.